Thermo Fisher Scientific (BSP:TMOS34) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Thermo Fisher Scientific Forward PE Ratio Related Terms
Thermo Fisher Scientific Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific Forward PE Ratio Chart
Thermo Fisher Scientific Annual Data
Trend
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
15.46
17.76
19.08
24.04
22.57
30.67
23.09
24.21
24.04
24.19
Thermo Fisher Scientific Quarterly Data
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
19.16
17.33
15.46
16.92
18.83
18.21
17.76
19.27
19.01
20.49
19.08
22.47
23.92
21.19
24.04
20.66
29.33
24.21
22.57
21.23
22.83
29.07
30.67
25.00
23.92
20.88
23.09
24.15
21.69
20.00
24.21
26.88
25.77
25.64
24.04
21.35
17.77
18.64
24.19
19.48
BSP:TMOS34 vs DHR, IDXX, A: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's Forward PE Ratio falls into.
Thermo Fisher Scientific Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Thermo Fisher Scientific (BSP:TMOS34) has a Forward PE Ratio of 20.85 as of Jul. 09, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Thermo Fisher Scientific and its competitors. According to the industry distribution chart, Thermo Fisher Scientific ranks #42 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 48.3%.
Is Thermo Fisher Scientific's Forward PE Ratio too high?
Thermo Fisher Scientific's current Forward PE Ratio is 20.85. The Medical Diagnostics & Research industry median Forward PE Ratio is 20.87. Thermo Fisher Scientific's value of 20.85 is 0.1% below this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #42 out of 87 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Forward PE Ratio compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #42 out of 87 companies for Forward PE Ratio. This puts Thermo Fisher Scientific in the upper half of its industry. The industry median Forward PE Ratio is 20.87. Thermo Fisher Scientific's value of 20.85 is 0.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 20.87, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current Forward PE Ratio of 20.85 is 0.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 20.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current Forward PE Ratio is 20.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$62.46, compared to a current price of R$54.46 — trading 12.8% below its estimated fair value. The current Forward PE Ratio is 20.85 and 0.1% below the Medical Diagnostics & Research industry median of 20.87. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current Forward PE Ratio is 20.85 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$54.46 is trading 12.8% below its estimated GF Value™ of R$62.46.
GuruFocus considers Thermo Fisher Scientific to be Modestly Undervalued.
Key valuation signals for BSP:TMOS34:
Forward PE Ratio: 20.85
GF Value™: R$62.46 vs. price of R$54.46 (12.8% below fair value)
Industry Position: 0.1% below the Medical Diagnostics & Research median (#42 of 87)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 